Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

SETD2 loss sensitizes cells to PI3Kβ and AKT inhibition.

Terzo EA, Lim AR, Chytil A, Chiang YC, Farmer L, Gessner KH, Walker CL, Jansen VM, Rathmell WK.

Oncotarget. 2019 Jan 18;10(6):647-659. doi: 10.18632/oncotarget.26567. eCollection 2019 Jan 18.

2.

Ultrasound Measurement of Vascular Density to Evaluate Response to Anti-Angiogenic Therapy in Renal Cell Carcinoma.

Rojas JD, Papadopoulou V, Czernuszewicz TJ, Rajamahendiran RM, Chytil A, Chiang YC, Chong DC, Bautch VL, Rathmell WK, Aylward S, Gessner RC, Dayton PA.

IEEE Trans Biomed Eng. 2019 Mar;66(3):873-880. doi: 10.1109/TBME.2018.2860932. Epub 2018 Jul 27.

PMID:
30059292
3.

Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy.

Rojas JD, Lin F, Chiang YC, Chytil A, Chong DC, Bautch VL, Rathmell WK, Dayton PA.

Theranostics. 2018 Jan 1;8(1):141-155. doi: 10.7150/thno.19658. eCollection 2018.

4.

Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells.

Pickup MW, Owens P, Gorska AE, Chytil A, Ye F, Shi C, Weaver VM, Kalluri R, Moses HL, Novitskiy SV.

Cancer Immunol Res. 2017 Sep;5(9):718-729. doi: 10.1158/2326-6066.CIR-16-0311. Epub 2017 Aug 3.

5.

Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.

Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, Freeman ML, Arteaga CL.

J Clin Invest. 2017 Mar 1;127(3):1116. doi: 10.1172/JCI93333. Epub 2017 Mar 1. No abstract available.

6.

TβRIII Expression in Human Breast Cancer Stroma and the Role of Soluble TβRIII in Breast Cancer Associated Fibroblasts.

Jovanović B, Pickup MW, Chytil A, Gorska AE, Johnson KC, Moses HL, Owens P.

Cancers (Basel). 2016 Nov 4;8(11). pii: E100.

7.

Deletion of the BMP receptor BMPR1a impairs mammary tumor formation and metastasis.

Pickup MW, Hover LD, Guo Y, Gorska AE, Chytil A, Novitskiy SV, Moses HL, Owens P.

Oncotarget. 2015 Sep 8;6(26):22890-904.

8.

TGFβ signaling in myeloid cells regulates mammary carcinoma cell invasion through fibroblast interactions.

Shaw AK, Pickup MW, Chytil A, Aakre M, Owens P, Moses HL, Novitskiy SV.

PLoS One. 2015 Jan 28;10(1):e0117908. doi: 10.1371/journal.pone.0117908. eCollection 2015.

9.

Age- and pregnancy-associated DNA methylation changes in mammary epithelial cells.

Huh SJ, Clement K, Jee D, Merlini A, Choudhury S, Maruyama R, Yoo R, Chytil A, Boyle P, Ran FA, Moses HL, Barcellos-Hoff MH, Jackson-Grusby L, Meissner A, Polyak K.

Stem Cell Reports. 2015 Feb 10;4(2):297-311. doi: 10.1016/j.stemcr.2014.12.009. Epub 2015 Jan 22.

10.

Attenuated transforming growth factor beta signaling promotes metastasis in a model of HER2 mammary carcinogenesis.

Novitskiy SV, Forrester E, Pickup MW, Gorska AE, Chytil A, Aakre M, Polosukhina D, Owens P, Yusupova DR, Zhao Z, Ye F, Shyr Y, Moses HL.

Breast Cancer Res. 2014 Oct 4;16(5):425. doi: 10.1186/s13058-014-0425-7.

11.

BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation.

Pickup MW, Hover LD, Polikowsky ER, Chytil A, Gorska AE, Novitskiy SV, Moses HL, Owens P.

Mol Oncol. 2015 Jan;9(1):179-91. doi: 10.1016/j.molonc.2014.08.004. Epub 2014 Aug 23.

12.

Role of TGF-β signaling in generation of CD39+CD73+ myeloid cells in tumors.

Ryzhov SV, Pickup MW, Chytil A, Gorska AE, Zhang Q, Owens P, Feoktistov I, Moses HL, Novitskiy SV.

J Immunol. 2014 Sep 15;193(6):3155-64. doi: 10.4049/jimmunol.1400578. Epub 2014 Aug 15.

13.

Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.

Jovanović B, Beeler JS, Pickup MW, Chytil A, Gorska AE, Ashby WJ, Lehmann BD, Zijlstra A, Pietenpol JA, Moses HL.

Breast Cancer Res. 2014 Jul 1;16(4):R69. doi: 10.1186/bcr3684.

14.

Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-β-deficient mouse mammary carcinomas.

Pickup MW, Laklai H, Acerbi I, Owens P, Gorska AE, Chytil A, Aakre M, Weaver VM, Moses HL.

Cancer Res. 2013 Sep 1;73(17):5336-46. doi: 10.1158/0008-5472.CAN-13-0012. Epub 2013 Jul 15.

15.

Lack of transforming growth factor-β signaling promotes collective cancer cell invasion through tumor-stromal crosstalk.

Matise LA, Palmer TD, Ashby WJ, Nashabi A, Chytil A, Aakre M, Pickup MW, Gorska AE, Zijlstra A, Moses HL.

Breast Cancer Res. 2012 Jul 2;14(4):R98. doi: 10.1186/bcr3217.

16.

Deletion of TGF-β signaling in myeloid cells enhances their anti-tumorigenic properties.

Novitskiy SV, Pickup MW, Chytil A, Polosukhina D, Owens P, Moses HL.

J Leukoc Biol. 2012 Sep;92(3):641-51. doi: 10.1189/jlb.1211639. Epub 2012 Jun 8.

17.

TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms.

Novitskiy SV, Pickup MW, Gorska AE, Owens P, Chytil A, Aakre M, Wu H, Shyr Y, Moses HL.

Cancer Discov. 2011 Oct;1(5):430-41. doi: 10.1158/2159-8290.CD-11-0100.

18.

Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.

Ijichi H, Chytil A, Gorska AE, Aakre ME, Bierie B, Tada M, Mohri D, Miyabayashi K, Asaoka Y, Maeda S, Ikenoue T, Tateishi K, Wright CV, Koike K, Omata M, Moses HL.

J Clin Invest. 2011 Oct;121(10):4106-17. doi: 10.1172/JCI42754. Epub 2011 Sep 19.

19.

Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators.

Owens P, Pickup MW, Novitskiy SV, Chytil A, Gorska AE, Aakre ME, West J, Moses HL.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2814-9. doi: 10.1073/pnas.1101139108. Epub 2011 May 16.

20.

Loss of one Tgfbr2 allele in fibroblasts promotes metastasis in MMTV: polyoma middle T transgenic and transplant mouse models of mammary tumor progression.

Fang WB, Jokar I, Chytil A, Moses HL, Abel T, Cheng N.

Clin Exp Metastasis. 2011 Apr;28(4):351-66. doi: 10.1007/s10585-011-9373-0. Epub 2011 Mar 4.

21.

Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung.

Yan HH, Pickup M, Pang Y, Gorska AE, Li Z, Chytil A, Geng Y, Gray JW, Moses HL, Yang L.

Cancer Res. 2010 Aug 1;70(15):6139-49. doi: 10.1158/0008-5472.CAN-10-0706. Epub 2010 Jul 14.

22.

Microdialysis combined with proteomics for protein identification in breast tumor microenvironment in vivo.

Xu BJ, Yan W, Jovanovic B, Shaw AK, An QA, Eng J, Chytil A, Link AJ, Moses HL.

Cancer Microenviron. 2010 Apr 13;4(1):61-71. doi: 10.1007/s12307-010-0046-3.

23.

Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer.

Bierie B, Chung CH, Parker JS, Stover DG, Cheng N, Chytil A, Aakre M, Shyr Y, Moses HL.

J Clin Invest. 2009 Jun;119(6):1571-82. doi: 10.1172/JCI37480. Epub 2009 May 18.

24.

GFAP-Cre-mediated activation of oncogenic K-ras results in expansion of the subventricular zone and infiltrating glioma.

Abel TW, Clark C, Bierie B, Chytil A, Aakre M, Gorska A, Moses HL.

Mol Cancer Res. 2009 May;7(5):645-53. doi: 10.1158/1541-7786.MCR-08-0477. Epub 2009 May 12.

25.

Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion.

Cheng N, Chytil A, Shyr Y, Joly A, Moses HL.

Mol Cancer Res. 2008 Oct;6(10):1521-33. doi: 10.1158/1541-7786.MCR-07-2203.

26.

Identification of novel Smad2 and Smad3 associated proteins in response to TGF-beta1.

Brown KA, Ham AJ, Clark CN, Meller N, Law BK, Chytil A, Cheng N, Pietenpol JA, Moses HL.

J Cell Biochem. 2008 Oct 1;105(2):596-611. doi: 10.1002/jcb.21860.

27.

Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment.

Bierie B, Stover DG, Abel TW, Chytil A, Gorska AE, Aakre M, Forrester E, Yang L, Wagner KU, Moses HL.

Cancer Res. 2008 Mar 15;68(6):1809-19. doi: 10.1158/0008-5472.CAN-07-5597.

28.

Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis.

Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC, Moses HL.

Cancer Cell. 2008 Jan;13(1):23-35. doi: 10.1016/j.ccr.2007.12.004.

29.

TGF-beta signaling is essential for joint morphogenesis.

Spagnoli A, O'Rear L, Chandler RL, Granero-Molto F, Mortlock DP, Gorska AE, Weis JA, Longobardi L, Chytil A, Shimer K, Moses HL.

J Cell Biol. 2007 Jun 18;177(6):1105-17.

30.
31.

Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.

Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, Freeman ML, Arteaga CL.

J Clin Invest. 2007 May;117(5):1305-13. Epub 2007 Apr 5. Erratum in: J Clin Invest. 2017 Mar 1;127(3):1116.

32.

Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor beta resistance and acquire paracrine mitogenic stimulation during progression.

Corsino P, Davis B, Law M, Chytil A, Forrester E, Nørgaard P, Teoh N, Law B.

Cancer Res. 2007 Apr 1;67(7):3135-44.

33.
34.

Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation.

Muñoz NM, Upton M, Rojas A, Washington MK, Lin L, Chytil A, Sozmen EG, Madison BB, Pozzi A, Moon RT, Moses HL, Grady WM.

Cancer Res. 2006 Oct 15;66(20):9837-44.

35.

Oncogenic function of a novel WD-domain protein, STRAP, in human carcinogenesis.

Halder SK, Anumanthan G, Maddula R, Mann J, Chytil A, Gonzalez AL, Washington MK, Moses HL, Beauchamp RD, Datta PK.

Cancer Res. 2006 Jun 15;66(12):6156-66.

36.

Effect of IGF-I in the chondrogenesis of bone marrow mesenchymal stem cells in the presence or absence of TGF-beta signaling.

Longobardi L, O'Rear L, Aakula S, Johnstone B, Shimer K, Chytil A, Horton WA, Moses HL, Spagnoli A.

J Bone Miner Res. 2006 Apr;21(4):626-36. Epub 2006 Apr 5.

37.
38.

Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks.

Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, Arteaga CL, Neilson EG, Hayward SW, Moses HL.

Oncogene. 2005 Jul 28;24(32):5053-68.

39.

Keratin 19 gene drives Cre recombinase expression throughout the early postimplantation mouse embryo.

Means AL, Chytil A, Moses HL, Coffey RJ Jr, Wright CV, Taketo MM, Grady WM.

Genesis. 2005 May;42(1):23-7.

PMID:
15828001
40.
41.

Inactivation of TGF-beta signaling in hepatocytes results in an increased proliferative response after partial hepatectomy.

Romero-Gallo J, Sozmen EG, Chytil A, Russell WE, Whitehead R, Parks WT, Holdren MS, Her MF, Gautam S, Magnuson M, Moses HL, Grady WM.

Oncogene. 2005 Apr 21;24(18):3028-41.

PMID:
15735717
42.

Contributions by members of the TGFbeta superfamily to lens development.

Beebe D, Garcia C, Wang X, Rajagopal R, Feldmeier M, Kim JY, Chytil A, Moses H, Ashery-Padan R, Rauchman M.

Int J Dev Biol. 2004;48(8-9):845-56.

43.

Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro.

Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL.

Neoplasia. 2004 Sep-Oct;6(5):603-10.

45.

Construction of a cyclin D1-Cdk2 fusion protein to model the biological functions of cyclin D1-Cdk2 complexes.

Chytil A, Waltner-Law M, West R, Friedman D, Aakre M, Barker D, Law B.

J Biol Chem. 2004 Nov 12;279(46):47688-98. Epub 2004 Sep 7.

46.

Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer.

Biswas S, Chytil A, Washington K, Romero-Gallo J, Gorska AE, Wirth PS, Gautam S, Moses HL, Grady WM.

Cancer Res. 2004 Jul 15;64(14):4687-92.

47.

TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia.

Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL.

Science. 2004 Feb 6;303(5659):848-51.

48.

Conditional inactivation of Tgfbr2 in cranial neural crest causes cleft palate and calvaria defects.

Ito Y, Yeo JY, Chytil A, Han J, Bringas P Jr, Nakajima A, Shuler CF, Moses HL, Chai Y.

Development. 2003 Nov;130(21):5269-80.

49.

Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells.

Law BK, Chytil A, Dumont N, Hamilton EG, Waltner-Law ME, Aakre ME, Covington C, Moses HL.

Mol Cell Biol. 2002 Dec;22(23):8184-98.

50.

Conditional inactivation of the TGF-beta type II receptor using Cre:Lox.

Chytil A, Magnuson MA, Wright CV, Moses HL.

Genesis. 2002 Feb;32(2):73-5. No abstract available.

PMID:
11857781

Supplemental Content

Loading ...
Support Center